Cargando…

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

Detalles Bibliográficos
Autores principales:	Back, David, Marzolini, Catia, Hodge, Catherine, Marra, Fiona, Boyle, Alison, Gibbons, Sara, Burger, David, Khoo, Saye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267419/ https://www.ncbi.nlm.nih.gov/pubmed/32384171 http://dx.doi.org/10.1111/bcp.14358

Ejemplares similares

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
por: Seden, Kay, et al.
Publicado: (2017)

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
por: Marra, Fiona, et al.
Publicado: (2020)

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
por: Stader, Felix, et al.
Publicado: (2018)

Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV
por: Jacobs, Tom G, et al.
Publicado: (2021)

Cobicistat: A case of mislabelled drug‐drug interaction risk?
por: Burger, David M., et al.
Publicado: (2020)

Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort
por: Kigen, Gabriel, et al.
Publicado: (2011)

Magnitude of Drug–Drug Interactions in Special Populations
por: Bettonte, Sara, et al.
Publicado: (2022)

Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
por: Bukkems, Vera E., et al.
Publicado: (2020)

Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs
por: Livio, Françoise, et al.
Publicado: (2019)

Drug classification for patients with comorbidities
por: Belialov, Farid
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study
por: Bettonte, Sara, et al.
Publicado: (2022)

Awareness of Drug–Drug Interaction in Elderly Patients with Osteoarthritis and Depression [Letter]
por: Zhu, Ling-Ling, et al.
Publicado: (2022)

Epilepsy Care- Awarness, Cost and Availability of Antiepileptic Drugs
por: Shubhakaran, Khichar
Publicado: (2021)

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
por: Girardin, François, et al.
Publicado: (2022)

Charles Bonnet Syndrome: Comorbidity may help in choosing the drug for therapy
por: Dubey, Ashok K
Publicado: (2013)

Drug-drug Interactions: The Importance of Medication Reconciliation
por: Makiani, Mahin Jamshidi, et al.
Publicado: (2017)

The challenge of HIV treatment in an era of polypharmacy
por: Back, David, et al.
Publicado: (2020)

Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series
por: Vazquez, Sara R., et al.
Publicado: (2022)

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
por: Grañana-Castillo, Sandra, et al.
Publicado: (2022)

Pediatricians’ awareness of galenic drugs for children with special needs: a regional survey
por: Burlo, Francesca, et al.
Publicado: (2023)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Drug-drug interaction with oral antivirals for the early treatment of COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2023)

Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy
por: Schulte, Benjamin, et al.
Publicado: (2020)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Primary hypothyroid induced by drug interaction
por: Diarra, Martin, et al.
Publicado: (2014)

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates
por: Bettonte, Sara, et al.
Publicado: (2023)

Drug-drug interaction with oral antivirals for early treatment of COVID-19 – Authors’ reply
por: Larsen, Carsten Schade
Publicado: (2023)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
por: Tod, M, et al.
Publicado: (2017)

Drug-micronutrient interactions: food for thought and thought for action
por: Karadima, Vasiliki, et al.
Publicado: (2016)

Response to “Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?”
por: Templeton, IE, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Interactions of recommended COVID-19 drugs with commonly used psychotropics
por: Chatterjee, Seshadri Sekhar, et al.
Publicado: (2020)

Proteomics in Host-Protozoan Parasite Interactions and Development of Drug and Vaccine
por: Kumar, Awanish
Publicado: (2021)

Potential interactions between COVID-19 vaccines and antiepileptic drugs
por: Kow, Chia Siang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0f95njd7i1p17pn6e7gr21bltp